Robert E. Funck Jr. - Feb 21, 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Robert E. Funck, Jr. by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Feb 21, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 05:29 PM
Previous filing
Sep 15, 2023
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +24.5K +12.37% $0.00 223K Feb 21, 2024 Direct F1
holding ABT Common shares without par value 20K Feb 21, 2024 By Trust F2
holding ABT Common shares without par value 20K Feb 21, 2024 By Trust F2
holding ABT Common shares without par value 18.8K Feb 21, 2024 Profit Sharing Trust F3
holding ABT Common shares without par value 500 Feb 21, 2024 By Daughter F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +92.1K $0.00 92.1K Feb 21, 2024 Common Shares 92.1K $116.98 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
F3 Balance in the Abbott Laboratories Stock Retirement Trust as of February 21, 2024.
F4 The reporting person disclaims beneficial ownership of all securities held by his daughter.
F5 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,712 on February 21, 2025, 30,712 on February 21, 2026, and 30,713 on February 21, 2027.